Heidi Espedal's picture

Heidi Espedal

Guest Researcher, + manager of the preclinical PET/CT facilities (MIC)
  • E-mailheidi.espedal@uib.no
  • Visitor Address
    Parkbygget, Haukeland Universitetssykehus
    7913, 0-floor
  • Postal Address
    Postboks 7804
    5020 Bergen
  • Show author(s) (2023). Fluid Flow visualization By PET-CT. 1 pages.
  • Show author(s) (2022). Lactate dehydrogenases promote glioblastoma growth and invasion via a metabolic symbiosis. EMBO Molecular Medicine. 1-20.
  • Show author(s) (2021). Repurposing 18F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy. Theranostics. 6044-6057.
  • Show author(s) (2021). Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. Communications Medicine. 1-14.
  • Show author(s) (2021). Of Rats and Rocks: using pre-clinical PET imaging facilities in core analysis.
  • Show author(s) (2021). Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer. Journal of Translational Medicine. 1-13.
  • Show author(s) (2021). Current landscape and future perspectives in preclinical MR and PET imaging of brain metastasis. Neuro-Oncology Advances (NOA). 14 pages.
  • Show author(s) (2021). Author Correction: Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis (Communications Medicine, (2021), 1, 1, (20), 10.1038/s43856-021-00019-x). Communications Medicine.
  • Show author(s) (2020). Trifluoperazine prolongs the survival of experimental brain metastases by STAT3-dependent lysosome membrane permeabilization. . American Journal of Cancer Research. 545-563.
  • Show author(s) (2020). Novel clearance of muscle proteins by muscle cells. European Journal of Cell Biology.
  • Show author(s) (2020). Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers. 1-18.
  • Show author(s) (2020). Comparison of bone regenerative capacity of donor-matched human adipose–derived and bone marrow mesenchymal stem cells. Cell and Tissue Research.
  • Show author(s) (2019). Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival. Cancers. 1-25.
  • Show author(s) (2019). Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood-brain barrier. Molecular Cancer Therapeutics. 2171-2181.
  • Show author(s) (2019). Imaging of preclinical endometrial cancer models for monitoring tumor progression and response to targeted therapy. Cancers. 1-16.
  • Show author(s) (2017). Lack of functional normalisation of blood vessels following anti-angiogenic therapy in glioblastoma. Journal of Cerebral Blood Flow and Metabolism. 1741-1753.
  • Show author(s) (2016). Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells. OncoTarget. 593-609.
  • Show author(s) (2016). Positron-Emission Tomography Offers New Insight Into Wormhole Formation. Journal of Petroleum Technology. 56-58.
  • Show author(s) (2016). New insight into wormhole formation in polymer gel during water chase floods with positron emission tomography. SPE Journal. 32-40.
  • Show author(s) (2016). New Insight to Wormhole Formation in Polymer Gel during Water Chasefloods using Positron Emission Tomography (PET).
  • Show author(s) (2015). Melanoma brain metastasis is independent of lactate dehydrogenase A expression. Neuro-Oncology. 1374-1385.
  • Show author(s) (2015). Intercellular transfer of transferrin receptor by a contact-, Rab8-dependent mechanism involving tunneling nanotubes. The FASEB Journal. 4695-4712.
  • Show author(s) (2015). Glycolysis in malignant brain tumors. Therapeutic implications for glioblastoma and melanoma brain metastasis.
  • Show author(s) (2015). Engraftment of human glioblastoma cells in immunocompetent rats through acquired immunosuppression. PLOS ONE.
  • Show author(s) (2015). Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathologica. 115-131.
  • Show author(s) (2014). Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment? Neuro-Oncology. 754-759.
  • Show author(s) (2012). Characterization of Lactate Dehydrogenase Expression in distinct Glioma Phenotypes.
  • Show author(s) (2010). The Expression and Localization of Id1 and Id3 in Glioblastoma Multiforme.
  • Show author(s) (1996). Satellite detection of natural films on the ocean surface. Geophysical Research Letters. 3151-3154.

More information in national current research information system (CRIStin)